Peptron, Inc. (087010.KQ)
KRW 98300.0
(-1.99%)
KRW 98300.0
(-1.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.65 Billion KRW | -33.46% |
| 2022 | -9.73 Billion KRW | 17.71% |
| 2021 | -11.73 Billion KRW | 14.33% |
| 2020 | -14.33 Billion KRW | -43.51% |
| 2019 | -10.05 Billion KRW | -51.34% |
| 2018 | -7 Billion KRW | -67.63% |
| 2017 | -4.17 Billion KRW | -41.11% |
| 2016 | -2.42 Billion KRW | -31.51% |
| 2015 | -2.07 Billion KRW | -10.9% |
| 2014 | -1.9 Billion KRW | -47.37% |
| 2013 | -1.37 Billion KRW | -637.62% |
| 2012 | -124.68 Million KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.56 Billion KRW | -10.2% |
| 2024 Q1 | -3.41 Billion KRW | -31.36% |
| 2023 Q4 | -2.54 Billion KRW | 26.9% |
| 2023 Q1 | -3.39 Billion KRW | -13.32% |
| 2023 Q3 | -3.48 Billion KRW | 28.85% |
| 2023 Q2 | -4.89 Billion KRW | -44.2% |
| 2023 FY | - KRW | -33.46% |
| 2022 Q4 | -2.99 Billion KRW | -3.69% |
| 2022 Q3 | -2.88 Billion KRW | 18.67% |
| 2022 Q2 | -3.55 Billion KRW | -175.04% |
| 2022 Q1 | -1.29 Billion KRW | 66.03% |
| 2022 FY | - KRW | 17.71% |
| 2021 Q3 | -3.81 Billion KRW | -304.89% |
| 2021 Q1 | -4.48 Billion KRW | -5.13% |
| 2021 FY | - KRW | 14.33% |
| 2021 Q2 | -941.4 Million KRW | 78.99% |
| 2021 Q4 | -3.8 Billion KRW | 0.27% |
| 2020 Q1 | -2.99 Billion KRW | -246.43% |
| 2020 FY | - KRW | -43.51% |
| 2020 Q4 | -4.26 Billion KRW | -21.25% |
| 2020 Q3 | -3.51 Billion KRW | 1.54% |
| 2020 Q2 | -3.57 Billion KRW | -19.38% |
| 2019 Q3 | -3.18 Billion KRW | -22.16% |
| 2019 Q2 | -2.6 Billion KRW | -48.91% |
| 2019 FY | - KRW | -51.34% |
| 2019 Q1 | -1.74 Billion KRW | -3.19% |
| 2019 Q4 | -863.36 Million KRW | 72.86% |
| 2018 Q1 | -1.26 Billion KRW | -3.25% |
| 2018 Q3 | -2.36 Billion KRW | -40.65% |
| 2018 FY | - KRW | -67.63% |
| 2018 Q4 | -1.69 Billion KRW | 28.43% |
| 2018 Q2 | -1.68 Billion KRW | -33.58% |
| 2017 Q3 | -860.31 Million KRW | 7.87% |
| 2017 Q2 | -933.77 Million KRW | 19.84% |
| 2017 Q1 | -1.16 Billion KRW | -26.42% |
| 2017 FY | - KRW | -41.11% |
| 2017 Q4 | -1.22 Billion KRW | -41.88% |
| 2016 Q3 | -684.36 Million KRW | -6.67% |
| 2016 Q1 | -714.49 Million KRW | -11.41% |
| 2016 FY | - KRW | -31.51% |
| 2016 Q2 | -641.59 Million KRW | 10.2% |
| 2016 Q4 | -921.5 Million KRW | -34.65% |
| 2015 Q3 | -630.13 Million KRW | -0.37% |
| 2015 FY | - KRW | -10.9% |
| 2015 Q4 | -641.29 Million KRW | -1.77% |
| 2015 Q2 | -627.83 Million KRW | -77.87% |
| 2015 Q1 | -352.96 Million KRW | 0.0% |
| 2014 FY | - KRW | -47.37% |
| 2014 Q2 | -428.77 Million KRW | 29.09% |
| 2014 Q1 | -604.64 Million KRW | 0.0% |
| 2014 Q3 | -494.46 Million KRW | -15.32% |
| 2013 FY | - KRW | -637.62% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 92.657% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -102.906% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 216.358% |
| Bioneer Corporation | 10.04 Billion KRW | 225.961% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -2789.403% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 34.763% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 70.441% |
| Helixmith Co., Ltd | -53 Billion KRW | 76.133% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 118.049% |
| Medy-Tox Inc. | 32.69 Billion KRW | 138.689% |
| Amicogen, Inc. | 13.95 Billion KRW | 190.664% |
| Genexine, Inc. | -40.87 Billion KRW | 69.053% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 253.72% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 82.278% |
| ALTEOGEN Inc. | 440.04 Million KRW | 2974.844% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 112.134% |
| SillaJen, Inc. | -17.35 Billion KRW | 27.097% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 214.924% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | -13.61% |
| Genomictree Inc. | -6.33 Billion KRW | -99.792% |
| MedPacto, Inc. | -32.6 Billion KRW | 61.205% |
| D&D Pharmatech | -9.05 Billion KRW | -39.663% |
| EASY BIO,Inc. | 24.32 Billion KRW | 152.01% |
| GI Innovation, Inc. | -51.33 Billion KRW | 75.355% |